Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Knight Therapeutics Inc.TSX: GUD.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of CA$94M rose 76.7% year over year, ahead of the +55.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Cost of revenue amounted to 66.5% of revenue in FY2025, up 13.5 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +76.7% holds above the trailing-twelve-month pace of +55.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$94M+14.3% QoQ
Last fiscal yearDec 2025
CA$299.35M+52.0% YoY
LTMMar 2026
CA$319.93M+55.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+76.7%——
1 year+52.0%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
299.35M CAD
Year-over-year change
+52.0%
4-year CAGR
+23.6%

Cost of Revenue vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +55.9% is the 4th highest of 8, against a peer median of +40.1%.
  • Cost of revenue amounts to 62.7% of revenue for GUD.TO, versus a peer median of 49.1%.
GUD.TO Competitors
Cost of Revenue for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$319.93M CAD+55.9%+24.4%62.7%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$282.6M CAD+116.3%—103.1%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$237.39M CAD+25.3%-20.7%76.4%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$218.14M CAD+40.1%+0.7%68.5%
TSND.TOTerrAscend Corp.LTM Mar 2026$128.47M USD-10.2%-13.4%49.1%
VHI.TOVitalhub Corp.LTM Mar 2026CA$30.05M CAD+109.3%+66.5%25.2%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$26.53M CAD+101.5%+46.4%39.9%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$12.97M USD+17.0%+63.9%25.5%
Peer median (excluding GUD.TO) —+40.1%+23.6%49.1%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue243.48M293.56M328.2M371.3M450.09M
Cost of Revenue128.07M155.5M175.55M196.9M299.35M
Gross Profit115.41M138.06M152.65M174.41M150.74M
Gross Margin47.4%47.0%46.5%47.0%33.5%
Research & Development12.69M14.76M17.55M23.3M28.98M
Selling, General & Admin74.38M88.62M83.69M99.35M123.96M
Operating Expenses128.24M155.12M155.54M167.01M152.94M
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
EBITDA42.59M25.26M40.9M64.38M54.37M
EBITDA Margin17.5%8.6%12.5%17.3%12.1%
Operating Income(5.32M)(2.4M)(2.89M)7.4M(2.2M)
Operating Margin-2.2%-0.8%-0.9%2.0%-0.5%
Interest Income7.38M10.63M12.58M10.41M6.21M
Interest Expense3.62M6.6M12.49M9.22M10.42M
Other Income / Expenses19.52M(2.92M)(19.1M)(5.35M)(4.5M)
Income Before Tax6.69M(43.96M)(21.99M)2.05M(6.7M)
Pre-Tax Margin2.7%-15.0%-6.7%0.6%-1.5%
Income Tax Expense(8.99M)(14.07M)(5.15M)(2.28M)(1.33M)
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Net Margin6.4%-10.2%-5.1%1.2%-1.2%
EPS (Basic)0.13(0.26)(0.16)0.04(0.05)
EPS (Diluted)0.13(0.26)(0.16)0.04(0.05)
Weighted Avg Shares124.48M114.89M107.47M101.04M99.57M
Weighted Avg Shares (Diluted)124.52M114.89M107.47M101.44M99.57M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.